(Q50854569)

24 March 2018

title

Effect of anticoagulant therapy on the hypercoagulable state in patients carrying the factor V Arg506Gln mutation. (English)

1 reference

24 March 2018

Torben Bjerregaard Larsen

1 reference

1

1 reference

24 March 2018

Ivan Brandslund

5

1 reference

ORCID Public Data File 2021

author name string

Lassen JF

2

1 reference

24 March 2018

Dahler-Eriksen BS

3

1 reference

24 March 2018

Petersen PH

4

1 reference

24 March 2018

Brandslund I

5

1 reference

24 March 2018

publication date

1 November 1998

1 reference

24 March 2018

published in

Thrombosis Research

1 reference

24 March 2018

volume

92

1 reference

24 March 2018

issue

4

1 reference

24 March 2018

page(s)

157-162

1 reference

24 March 2018

Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900123-6

7 January 2021

Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900123-6

7 January 2021

Mutation in blood coagulation factor V associated with resistance to activated protein C.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900123-6

7 January 2021

The Arg506Gln mutation (FV Leiden) among a cohort of 4188 unselected Danish newborns

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900123-6

7 January 2021

Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900123-6

7 January 2021

The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900123-6

7 January 2021

Resistance to activated protein C as a basis for venous thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900123-6

7 January 2021

Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900123-6

7 January 2021

Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900123-6

7 January 2021

Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-->Gln mutation in the gene for factor V

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900123-6

7 January 2021

Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900123-6

7 January 2021

Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900123-6

7 January 2021

Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors. East Anglian Thrombophilia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900123-6

7 January 2021

Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900123-6

7 January 2021

10.1016/S0049-3848(98)00123-6

Identifiers

DOI

1 reference

24 March 2018

1 reference

24 March 2018